Company news
RemeGen Co. Ltd. news in 2026
RemeGen Co. Ltd.'s news releases, calls and decks from 2026, newest first.
(688331)"REMEGEN CO., LTD."Announcement on Shareholdings of Top 10 Shareholders and Top 10 Shareholders Holding Unrestricted Shares Concerning the Second Share Repurchase in 2026
November 4, 2026
(688331)"REMEGEN CO., LTD."Proposal on the Second Share Repurchase through Call Auction in 2026
November 2, 2026
(688331)"REMEGEN CO., LTD."Announcement on Resolutions of the 6th Meeting of the 3rd Board of Directors
November 2, 2026
(688331)"REMEGEN CO., LTD."Announcement on Progress of Initial Repurchase of Shares through Call Auction in 2026
November 2, 2026
(688331)"REMEGEN CO., LTD."Report for Q3 2026
October 29, 2026
(688331)"REMEGEN CO., LTD."Announcement on Resolutions of the 5th Meeting of the 3rd Board of Directors
October 29, 2026
(688331)"REMEGEN CO., LTD."Announcement on Proposal by the Actual Controller and Chairman for the Company to Repurchase Shares
October 28, 2026
(688331)"REMEGEN CO., LTD."Announcement on the Company's Recent Production and Operation
October 23, 2026
(688331)"REMEGEN CO., LTD."Announcement on Progress of Initial Repurchase of Shares through Call Auction in 2026
October 8, 2026
Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug Industry
September 7, 2026
Announcement on Adjustment of Members of Special Committees of the Board of Directors
August 24, 2026
Announcement on Voluntary Disclosure of Semi-annual Performance Forecast for 2026
August 5, 2026
Announcement on Progress of the First Repurchase of Company Shares in 2026 through Call Auction
August 3, 2026
Announcement on the First Share Repurchase through Call Auction in 2026
July 30, 2026
Announcement on Shareholdings of Top 10 Shareholders and Top 10 Shareholders of Unrestricted Shares Concerning First Share Repurchase in 2026
July 21, 2026
Announcement on Resolutions of the 2nd Meeting of the 3rd Board of Directors
July 19, 2026
Announcement on Circulation of Restricted Shares in Initial Public Offering
June 22, 2026
Announcement on Election of Employee Representative Directors for the 3rd Board of Directors
June 16, 2026
Announcement on Voluntary Disclosure of the Conditional Marketing Application for Telitacicept for the Treatment of IgA Nephropathy
June 8, 2026
Notice on Convening the 2025 Annual General Meeting
May 20, 2026
Announcement on Resolutions of the 38th Meeting of the 2nd Board of Directors
May 18, 2026
Announcement on Participation in the "Dialogue on Growth" 2025 and Q1 2026 Collective Performance Briefing
May 6, 2026
Report for Q1 2026
April 28, 2026
Science and Technology for People's Well-being - Achievement of Enterprises on SSE STAR Market and Its Empowerment of People's Livelihood Conference
April 27, 2026
Announcement on Voluntary Disclosure of Approval of Marketing Application for Vedicizumab as the First-line Treatment for HER2-Low Expressing Urothelial Carcinoma
April 10, 2026
Announcement on Voluntary Disclosure of Notice of Approval for Drug Clinical Trial Application Obtained by Dual-antibody ADC Drug RC288 for Injection
April 1, 2026
2025 Annual Report
March 27, 2026
Announcement on Voluntary Disclosure of Approval of Marketing Application for Vedicizumab the Treatment of HER2-Low Expressing Breast Cancer with Liver Metastasis
March 23, 2026
Announcement on Changing Signatory Certified Public Accountant
February 27, 2026
Earnings Preannouncement for 2025
January 30, 2026
Announcement on Vesting Results of Relevant Rights in the Related Vesting Period of the 2022 and 2023 A-share Restricted Stock Incentive Plans and Shares Listing
January 21, 2026
Announcement on Completion of Initial Share Repurchase and Implementation of Share Repurchase Plan
January 20, 2026
Announcement on Adjusting Upper Limit of Shares Repurchase Price
January 15, 2026
Announcement on Signing a Licensing Agreement with AbbVie
January 12, 2026
Announcement on Progress in Repurchasing Shares through Call Auction
January 5, 2026